BIIB - Biogen Inc logo

BIIB

Biogen Inc

Biogen Inc. develops, manufactures, and commercializes therapies primarily for neurological and neurodegenerative diseases, offering products for multiple sclerosis, spinal muscular atrophy, Alzheimer's, and various autoimmune conditions.

โš•๏ธ Healthcare NASDAQ Listed 1991 $ USD
$1,000 invested 30 years ago โ†’$65,528today

Score Overview

1 Year
Score
Net Growth-35.43%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth1.40%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.1
Net Growth-46.33%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-9.41%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-77.45%
Net Trend40%
Net Income Consistency
Rev Growth-13.11%
Rev Trend50%
Revenue Consistency
20 Years
Score5.7
Net Growth283.93%
Net Trend70%
Net Income Consistency
Rev Growth270.77%
Rev Trend75%
Revenue Consistency
30 Years
Score
Net Growth20x
Net Trend70%
Net Income Consistency
Rev Growth35x
Rev Trend77%
Revenue Consistency
All Time
Score
Net Growth115x
Net Trend69%
Net Income Consistency
Rev Growth162x
Rev Trend77%
Revenue Consistency

See the full market ranking โ†’

Biogen Inc fundamental performance

Between 2005 and 2025, revenue grew from $ 1.71B to $ 9.81B and net income grew from $ 160M to $ 1.29B. Revenue increased in 15 of those 20 years; net income in 14.

Across Biogen Inc's full reported history, from 1991 to 2025, revenue grew from $ 61M to $ 9.81B and net income grew from $ 7M to $ 1.29B. Revenue increased in 77% of the years measured; net income in 69%.

Biogen Inc currently holds a 20-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 208.87โ€”
1 Year2025-08-12
$ 128.9362.00%
5 Years2021-08-12
$ 340.68-38.69%
10 Years2016-08-12
$ 313.94-33.47%
20 Years2006-08-11
$ 41.45403.91%
30 Years1996-08-12
$ 3.1965x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 9.94B$ 835M$ 1.28B
2025$ 9.81B$ 1.29B$ 3.81B
2024$ 9.67B$ 1.63B$ 2.37B
2023$ 9.83B$ 1.16B$ 1.04B
2022$ 10.17B$ 3.04B$ 4.89B
2021$ 10.98B$ 1.55B$ 3.80B
2020$ 13.44B$ 4.00B$ 2.61B
2019$ 14.37B$ 5.88B$ 4.47B
2018$ 13.45B$ 4.43B$ 3.53B
2017$ 12.27B$ 2.53B$ 3.68B
2016$ 11.44B$ 3.70B$ 4.89B
2015$ 10.76B$ 3.54B$ 3.42B
2014$ 9.70B$ 2.93B$ 1.84B
2013$ 6.93B$ 1.86B$ 1.22B
2012$ 5.51B$ 1.38B$ 1.70B
2011$ 5.04B$ 1.23B$ 1.69B
2010$ 4.71B$ 1.00B$ 1.20B
2009$ 4.37B$ 970M$ 1.26B
2008$ 4.09B$ 783M$ 1.37B
2007$ 3.17B$ 638M$ 1.18B
2006$ 2.68B$ 217M$ 902M
2005$ 1.71B$ 160M$ 850M
2004$ 1.59B$ 25M$ 1.05B
2003$ 186M-$ 875M$ 835M
2002$ 404M$ 148M$ 867M
2001$ 1.04B$ 272M$ 798M
2000$ 925M$ 333M$ 682M
1999$ 794M$ 220M$ 654M
1998$ 557M$ 138M$ 516M
1997$ 434M$ 89M$ 440M
1996$ 277M$ 40M$ 321M
1995$ 151M$ 5M$ 307M
1994$ 156M-$ 4M$ 267M
1993$ 136M$ 32M$ 74M
1992$ 123M$ 38M$ 85M
IPO1991$ 61M$ 7M$ 56M

Explore beyond BIIB

You're looking at Biogen Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies